U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H16N2O4
Molecular Weight 276.2878
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Y-26763

SMILES

[H][C@@]1([C@H](O)C(C)(C)OC2=CC=C(C=C12)C#N)N(O)C(C)=O

InChI

InChIKey=IWTCFIIOUXJOOV-OLZOCXBDSA-N
InChI=1S/C14H16N2O4/c1-8(17)16(19)12-10-6-9(7-15)4-5-11(10)20-14(2,3)13(12)18/h4-6,12-13,18-19H,1-3H3/t12-,13+/m1/s1

HIDE SMILES / InChI

Molecular Formula C14H16N2O4
Molecular Weight 276.2878
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Y-26763 is an active metabolite of Y-27152. Y-26763 is the novel K channel opener. It has been found to activate K channels in both cardiac myocytes and in smooth muscle cells from various tissues, suggesting that the compound has a non-specific effect on SUR1 and SUR2 channel subunits. Y-26763 well tolerated in healthy volunteers, and its pharmacologic effects were likely caused by vasodilation, which could make it an effective antihypertensive agent. At doses of 0.5 mg or higher, participants experienced headaches and palpitations, which were probably due to the vasodilatory effects and did not require treatment. Y-26763 partially protected against glycerol-induced acute renal failure. Also, it reduces infarct volume in focal cerebral ischemia in rats.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
1 mg 1 times / day multiple, oral (unknown)
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
healthy
n = 9
Health Status: healthy
Sex: M
Food Status: UNKNOWN
Population Size: 9
Sources:
Other AEs: headache...
Other AEs:
headache
Sources:
AEs

AEs

AESignificanceDosePopulation
headache
1 mg 1 times / day multiple, oral (unknown)
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
healthy
n = 9
Health Status: healthy
Sex: M
Food Status: UNKNOWN
Population Size: 9
Sources:
PubMed

PubMed

TitleDatePubMed
Effects of Y-26763, a novel K-channel opener, on electrical responses of smooth muscles in the guinea pig bladder.
1996 Apr
Y-26763 protects the working rat myocardium from ischemia/reperfusion injury through opening of KATP channels.
1996 Dec 19
Altered cerebrovascular response to a potassium channel opener in hypertensive rats.
1996 Jul
Age-related changes in response of brain stem vessels to opening of ATP-sensitive potassium channels.
1997 Jan
Role of potassium channels in halothane-epinephrine arrhythmias.
1998 Jun
Long-term effects of benidipine on cerebral vasoreactivity in hypertensive rats.
2002 Mar 8
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Y-27152 itself is pharmacologically inert and is converted to its active form, Y-26763, after oral administration.
In the first phase, single doses of 0.1, 0.25, 0.5, 0.75, and 1.0 mg of Y-27152 were given after overnight fasts in a dose-escalating manner. The 0.75-mg dose was given both after an overnight fast or after food to examine the effects of food intake. In the second phase, multiple doses of Y-27152 were taken after meals once daily for 7 consecutive days. In part A of this phase, either placebo or 0.5 mg of Y-27152 was taken for 7 days, and in part B of this phase 0.5-, 0.75-, and 1.0-mg doses were taken in a dose-escalating manner for 1,3, and 3 days, respectively.
Route of Administration: Oral
In Vitro Use Guide
Y-26763 concentration dependently relaxed the contraction induced by 20 mM KCL in rat aortic rings with an IC50 value of 0.027 uM, being ineffective against 80 mM KCL contraction.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:59:31 GMT 2023
Edited
by admin
on Fri Dec 15 17:59:31 GMT 2023
Record UNII
Q9F3XV8A6X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Y-26763
Common Name English
ACETAMIDE, N-((3S,4R)-6-CYANO-3,4-DIHYDRO-3-HYDROXY-2,2-DIMETHYL-2H-1-BENZOPYRAN-4-YL)-N-HYDROXY-
Systematic Name English
(3S,4R)-(N-ACETYL-N-HYDROXY)AMINO-6-CYANO-3,4-DIHYDRO- 2,2-DIMETHYL-2H-1-BENZOPYRAN-3-OL, (+)
Common Name English
Y 26763
Code English
Code System Code Type Description
FDA UNII
Q9F3XV8A6X
Created by admin on Fri Dec 15 17:59:31 GMT 2023 , Edited by admin on Fri Dec 15 17:59:31 GMT 2023
PRIMARY
EPA CompTox
DTXSID80155562
Created by admin on Fri Dec 15 17:59:31 GMT 2023 , Edited by admin on Fri Dec 15 17:59:31 GMT 2023
PRIMARY
CAS
127408-31-5
Created by admin on Fri Dec 15 17:59:31 GMT 2023 , Edited by admin on Fri Dec 15 17:59:31 GMT 2023
PRIMARY
PUBCHEM
121878
Created by admin on Fri Dec 15 17:59:31 GMT 2023 , Edited by admin on Fri Dec 15 17:59:31 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY